Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression analysis in canine epitheliotropic lymphoma - validation cohort

ABSTRACT: We performed targeted transcriptomic analysis on archival biopsies from client-owned dogs to examine immune and skin gene expression profiles in spontaneous canine epitheliotropic lymphoma (EL).

ORGANISM(S): Canis lupus familiaris

PROVIDER: GSE213086 | GEO | 2023/10/26

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression analysis in canine epitheliotropic lymphoma - discovery cohort

Project description:We performed targeted transcriptomic analysis on archival biopsies from client-owned dogs to examine immune and skin gene expression profiles in spontaneous canine epitheliotropic lymphoma (EL).

2023-10-26 | GSE211988 | GEO

Gene expression analysis in canine diffuse large B cell lymphoma (DLBCL)

Project description:We performed a veterinary clinical oncology trial in client-owned dogs to determine if immune modulating drugs could be combined in rational approaches to treat spontaneous canine diffuse large B cell lymphoma (DLBCL).

2023-08-29 | GSE213088 | GEO

Gene expression analysis in canine pemphigus

Project description:We performed a comparative immunology case study of client-owned dogs to determine if immune and skin gene expression profiles in spontaneous canine pemphigus mirror those observed in human pemphigus

2021-09-20 | GSE171079 | GEO

Gene expression analysis in canine Vogt-Koyanagi-Harada/uveodermatologic syndrome and vitiligo

2020-12-17 | GSE154024 | GEO

Gene expression analysis in canine discoid/chronic lupus erythematosus, mucocutaneous lupus erythematosus and pyoderma

2022-03-23 | GSE160260 | GEO

Gene expression analysis in complex canine chronic cutaneous lupus erythematosus (CCLE)

2022-02-11 | GSE180276 | GEO

Proteomic characterization of canine gastric fluid by liquid chromatography mass spectrometry (LCMS) for development of protein biomarkers in regurgitation, vomiting, and cough

Project description:Reflux and aspiration in people cause and exacerbate respiratory diseases in the absence of gastrointestinal (GI) signs. Protein biomarkers in humans detect extra-esophageal reflux (EER) from oropharyngeal (OP) and bronchoalveloar lavage samples. Reflux likely contributes to respiratory disease in dogs. The objectives of this study were to analyze the canine gastric fluid (GF) proteome and compare this to the OP proteome in normal, vomiting/regurgitating and coughing dogs to identify biomarkers for EER/aspiration. Twenty-three client-owned dogs were enrolled. Canine GF samples (n=5) and OP swabs in normal (n=6), vomiting/regurgitating (n=7), and coughing (n=5) dogs were within 2 weeks of sample collection. Protein digests were analyzed by liquid chromatography mass spectrometry (LCMS). Differential abundance (DA) of proteins between groups was evaluated by Fisher Exact test with p< 0.0004 significance level after correction for multiple comparisons. DA was found between all groups (P <0.0001): GF versus normal (n=130 proteins), cough versus normal (n=22 proteins), vomiting/regurgitating versus normal (n=20 proteins). Protein abundance was highly variable between dogs. Gastrointestinal-specific proteins were found in OP swabs from vomiting/regurgitating and coughing dogs but not healthy dogs. In conclusion, the proteomic composition of the OP varies between health and disease. Presence of gastrointestinal-specific proteins in OP of coughing dogs may suggest reflux and/or aspiration as contributing factors. Variable protein abundance warrants investigation into biomarker panels.

2021-04-12 | MSV000087178 | MassIVE

RNA-Seq analysis of gene expression in 25 cases of canine lymphoma undergoing CHOP chemotherapy

Project description:Canine lymphoma is the most common hematological cancer in dogs and shares many molecular and clinical characteristics with human Non-Hodgkin lymphoma (NHL). The standard treatment for canine lymphoma is the “CHOP” sequential multiagent chemotherapy protocol consisting of Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Vincristine (Oncovin™), and Prednisone. Approximately 70 - 85% of patients treated with CHOP achieve clinical remission. However, duration of remission varies and the majority of dogs eventually relapse. To identify possible biomarkers for patients failing to achieve remission in response to CHOP, we performed RNA-Seq analysis on 25 cases of canine lymphoma taken at the start of their CHOP therapy regime, and determined patient progression free survival (PFS).

2020-01-01 | GSE130874 | GEO

Gene expression analysis in canine epitheliotropic lymphoma - validation cohort

Project description:Gene expression analysis in canine epitheliotropic lymphoma - validation cohort

| PRJNA879075 | ENA

Next gen RNA sequencing of canine lymphoma

Project description:Transcriptome analysis of lymphoma samples were performed to assess EGFR and PLAUR/uPAR expression profiles and compare to human tumors from TCGA. Abstract Sarcomas differ from carcinomas in their mesenchymal origin. Therapeutic advancements have come slowly so alternative drugs and models are urgently needed. These studies report a new drug for sarcomas that simultaneously targets both tumor and tumor neovasculature. eBAT is a bispecific angiotoxin consisting of truncated, deimmunized Pseudomonas exotoxin fused to epidermal growth factor (EGF) and the amino terminal fragment (ATF) of urokinase. Here, we study the drug in an in vivo “ontarget” companion dog trial since eBAT effectively kills canine hemangiosarcoma (HSA) and human sarcoma cells in vitro. We reasoned the model has value due to the common occurrence of spontaneous sarcomas in dogs and a limited lifespan allowing for rapid accrual and data collection. Splenectomized dogs with minimal residual disease were given one cycle of eBAT followed by adjuvant doxorubicin in an adaptive dose-finding, phase I- II study of 23 dogs with spontaneous, stage I-II, splenic HSA. eBAT improved 6-month survival from <40% in a comparison population to ~70% in dogs treated at a biologically active dose (50 μg/kg). Six dogs were long-term survivors, living >450 days. eBAT abated expected toxicity associated with EGFR-targeting, a finding supported by mouse studies. Urokinase plasminogen activator receptor (uPAR) and EGFR are targets for human sarcomas, so thorough evaluation is crucial for validation of the dog model. Thus, we validated these markers for human sarcoma targeting in the study of 212 human and 97 canine sarcoma samples. Our results support further translation of eBAT for human patients with sarcomas and perhaps other EGFR-expressing malignancies.

2017-02-23 | GSE95184 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data